---
id: 121
title: Candida Species and Candidemia Management
category: organisms
subcategory: fungi
tags: [Candida, candidemia, echinocandins, fluconazole, C-auris, fungemia]
difficulty: medium
---

## Question

How is candidemia managed? Use the **"Echinocandin First-Line + Remove Lines + Ophthalmology Exam + 14 Days After Clearance"** framework.

## Answer

### **Candidemia Management Principles:**

**1. Source Control:**
- **Remove ALL central venous catheters** (within 24-48h if possible)
- **Remove other infected devices** (urinary catheters, drains)

**2. Empiric Therapy:**
- **Echinocandin** (caspofungin, micafungin, or anidulafungin) - **First-line**

**3. Repeat Blood Cultures:**
- **Daily until clearance** (negative blood cultures)

**4. Ophthalmology Exam:**
- **Within 1 week** (screen for endophthalmitis)

**5. Duration:**
- **14 days AFTER first negative blood culture** + resolution of symptoms

### **Treatment by Species and Susceptibility:**

| Species | Empiric Therapy | De-escalation (if susceptible) | Resistance Notes |
|---------|----------------|-------------------------------|------------------|
| ***C. albicans*** | **Echinocandin** (caspofungin 70mg × 1 → 50mg daily) | **Fluconazole 800mg × 1 → 400mg daily** (if stable + susceptible) | Usually fluconazole-susceptible |
| ***C. glabrata*** | **Echinocandin** | **Echinocandin** (or high-dose fluconazole if susceptible dose-dependent) | **Often azole-resistant** |
| ***C. parapsilosis*** | **Fluconazole 800mg × 1 → 400mg daily** (if susceptible) OR echinocandin | **Fluconazole** preferred (echinocandins have higher MICs) | Usually fluconazole-susceptible |
| ***C. auris*** | **Echinocandin** | **Echinocandin** (pan-resistance common) | **Multidrug-resistant** (MDR), infection control critical |
| ***C. krusei*** | **Echinocandin** | **Echinocandin** OR **voriconazole** | **Intrinsically fluconazole-resistant** |

### **Specific Clinical Scenarios:**

**Non-Neutropenic, Hemodynamically Stable:**
- **Echinocandin × 5-7 days** → step down to **fluconazole 400mg daily** (if *C. albicans* or susceptible species)

**Neutropenic or Critically Ill:**
- **Echinocandin** (continue entire course, avoid step-down)

**Fluconazole-Susceptible + Clinically Stable:**
- Can step down to **fluconazole 400mg daily** after 5-7 days of echinocandin (if clearance documented)

## Key Points

### **Why Echinocandin First-Line:**
- **Fungicidal** (vs fluconazole bacteriostatic)
- **Broad-spectrum** (covers azole-resistant *Candida*)
- **Excellent safety profile** (minimal drug interactions, low toxicity)
- **Superior outcomes** vs fluconazole in critically ill/neutropenic

### **Candida Endophthalmitis:**
- **Screen ALL candidemia patients** (ophthalmology exam within 1 week)
- **Incidence:** 5-10% of candidemia cases
- **Symptoms:** Often asymptomatic (requires dilated fundoscopic exam)
- **Treatment:** **Voriconazole 6 mg/kg IV q12h × 2 → 4 mg/kg q12h** (better vitreous penetration than echinocandins) + consider **intravitreal antifungal** + **vitrectomy** (if severe)

### ***Candida auris*:**
- **Emerging MDR pathogen** (first identified 2009, now global)
- **Often pan-resistant** (fluconazole, amphotericin B resistance common; echinocandin resistance emerging)
- **Transmission:** Healthcare-associated, environmental persistence
- **Infection control:** **Contact precautions**, **single-patient rooms**, **enhanced cleaning** (quaternary ammonium or chlorine-based disinfectants)
- **Treatment:** **Echinocandin** (if susceptible) OR **amphotericin B** (if echinocandin-resistant)

### **Duration:**
- **14 days AFTER first negative blood culture**
- **Longer if:** Endocarditis (6 weeks), osteomyelitis (6-12 months), persistent fungemia (investigate for undrained source)

### **Clinical Pearls:**
- **Echinocandin first-line** for candidemia
- **Remove ALL central lines** within 24-48h
- **Repeat cultures daily** until clearance
- **Ophthalmology exam within 1 week** (screen for endophthalmitis)
- **14 days after clearance** (first negative culture)
- ***C. parapsilosis*:** Fluconazole preferred (if susceptible)
- ***C. auris*:** MDR, echinocandin (infection control critical)

## Sources

- [IDSA: Candidiasis Guidelines 2024]
- [CDC: *C. auris* Interim Guidance 2024]

## Media

N/A
